PDF Cover

Veterinary Biologics Market

The market for Veterinary Biologics was estimated at $3.1 billion in 2024; it is anticipated to increase to $4.3 billion by 2030, with projections indicating growth to around $5.8 billion by 2035.

Report ID:DS1806096
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Other Healthcare
Veterinary Biologics
Share
Connect
Report Price: $4,200
Report Summary
Market Data
Methodology
Table of Contents

Global Veterinary Biologics Market Outlook

Revenue, 2024

$3.1B

Forecast, 2034

$5.4B

CAGR, 2025 - 2034

5.8%

The Veterinary Biologics industry revenue is expected to be around $3.3 billion in 2025 and expected to showcase growth with 5.8% CAGR between 2025 and 2034. The veterinary biologics market has evolved into a vital segment of the worldwide animal health industry because people spend more on their pets and farmers need better disease control for their livestock and both developed and developing nations focus on protecting human health and food security. The market demand for veterinary hospitals and clinics and veterinary diagnostic labs combined reaches 90.3% because these facilities determine customer purchasing decisions through their clinical and diagnostic services. The product segment of diagnostic kits generated $1.27 billion in revenue during 2024 because these products serve as essential tools for fast disease detection and monitoring and everyday veterinary practice.

Veterinary biologics consist of veterinary vaccines and bacterins and antisera and toxoids and immunomodulators and in vitro reagents which help prevent and diagnose and treat infectious and immune related diseases in animals to promote complete animal wellness and enhanced production levels. The immune system activation through targeted mechanisms combined with species safe profiles and diagnostic program integration reduces pharmaceutical usage for achieving sustained disease management. The main uses of veterinary biologics include essential and additional vaccination schedules and disease control for animal groups and surgical and chronic disease management and veterinary facility and laboratory diagnostic procedures. The market demand for veterinary biologics grows because of two main factors: veterinarians now use more recombinant and vector based vaccines and manufacturers develop monoclonal antibody based products and point of care diagnostic kits become more available and biotechnology advances integrate better with surveillance systems. Veterinary biologics have become more vital for modern animal health systems because of increasing demand for recombinant and vector based vaccines and monoclonal antibody based products and point of care diagnostic kits and real time surveillance integration.

Veterinary Biologics market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Veterinary Biologics Market Outlook

Market Key Insights

  • The Veterinary Biologics market will expand from $3.1 billion in 2024 to reach $5.4 billion during the period from 2024 to 2034. The market will expand at a 5.8% annual rate because customers need more products for Infectious Disease Prevention and Veterinary Dermatology and Diagnostic Testing.

  • Biogénesis Bagó, Boehringer Ingelheim Animal Health, and Ceva Santé Animale are among the leading players in this market, shaping its competitive landscape.

  • The Veterinary Biologics market depends on the United States and China as its leading customer bases which will experience growth at 3.8% to 5.6% CAGR from 2024 to 2030.

  • The market research predicts that India, Brazil and Mexico will experience the most rapid expansion with CAGR rates between 6.7% and 8.0%.

  • Transition like Shift To Precision Immunotherapies has greater influence in U.S. and China market's value chain; and is expected to add $128 million of additional value to Veterinary Biologics industry revenue by 2030.

    .

  • The Veterinary Biologics market will experience a $2.3 billion expansion from 2024 to 2034 while manufacturers focus on Dermatology & Oncology Application to achieve higher market penetration.

  • With

    rising companion animal ownership and intensifying zoonotic disease risks accelerating innovation in veterinary biologics, and

    Advances in recombinant vaccine platforms transforming product pipelines and lifecycle management in veterinary biologics, Veterinary Biologics market to expand 76% between 2024 and 2034.

veterinary biologics market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Veterinary Biologics - Country Share Analysis

Opportunities in the Veterinary Biologics

The United States and Canada have also pet owners who want sophisticated non invasive cancer treatments for their dogs and cats thus creating a specific market for veterinary biologics based on monoclonal antibodies. The worldwide market for mAbs reached USD 0.70 billion in 2024 and experts predict it will expand to USD 1.03 billion by 2030 at a 6.7% annual growth rate. The market for companion animal oncology biologics will experience maximum expansion through specialty clinics and corporate hospital chains because insurance companies start to cover expensive biologic treatments.

Growth Opportunities in North America and Asia-Pacific

The veterinary biologics market in North America depends on its developed animal health industry and advanced pet care systems which Veterinary Hospitals & Clinics lead because they quickly embrace new animal vaccines and companion animal biologics for preventive and specialty care. The market competition remains intense because multinational companies and regional specialists fight for market share through their unique biologic offerings and complete product life cycles and customized practice support services which enable them to charge higher prices for veterinary immunotherapy and new adjuvant technologies and combined biologic solutions. The market depends on three main factors which include high pet insurance coverage and customer readiness to spend on advanced medical procedures and strong regulatory support for safe and effective products with good pharmacovigilance practices. The product positioning requires three essential elements which include practice integration and data driven outcomes evidence and continuing education programs to succeed in this market. The strategic growth plan involves two main initiatives which include building stronger ties with corporate clinic networks and creating biologic treatment protocols for standard care procedures and providing complete diagnostic and treatment solutions that connect Veterinary Diagnostic Labs to the regional veterinary biologics market.
The veterinary biologics market in Asia Pacific experiences growing influence from extensive disease management initiatives and advanced animal health systems which make the Others End User segment consisting of government bodies and large commercial farms and producer cooperatives the most important because they conduct centralized procurement and execute large scale vaccination programs. The market competition exists between international companies and domestic manufacturers who compete through affordable prices and complete product lines and dependable delivery systems for large animal vaccine requirements. The market experiences growing demand for animal protein and strict biosecurity standards and frequent animal disease outbreaks which drive customers to seek fast manufacturing solutions and cold chain protection for their herd level companion animal biologics needs. The market demands strategic product development that matches local disease patterns and surveillance system integration with Veterinary Diagnostic Labs and multiple pricing tiers for different customer segments and extended warranty programs through public private vaccination programs to maintain customer loyalty.

Market Dynamics and Supply Chain

01

Driver: Rising companion animal ownership and intensifying zoonotic disease risks accelerating innovation in veterinary biologics

The increasing number of people who keep pets as companions leads to new veterinary biologics requirements because owners want advanced medical treatments for their pets similar to human medicine. The veterinary biologics industry focuses on developing new products for treating chronic diseases and dermatological conditions and cancer in companion animals to enhance their health and life quality. The growing threat of zoonotic diseases has also led to increased funding for advanced livestock vaccines and localized vaccination initiatives because authorities and producers understand the need for effective zoonotic disease control measures. The development of new adjuvants and recombinant antigens and delivery systems aims to improve herd health outcomes and maintain livestock productivity in dense agricultural operations. The market structure of veterinary biologics is also becoming more complex because companies must also speed up their research efforts and build adaptable production facilities and improve their cold chain distribution systems.

The development of recombinant vaccine platforms also serves as a major expansion driver for veterinary biologics because it also creates safe vaccines with precise animal targeting and enhanced immune responses. The fast development of new vaccine strains becomes possible through recombinant subunit and vector based and virus like particle technologies which match the requirements of precision livestock farming. The platforms enable DIVA strategies which reduce regulatory complexities and surveillance requirements and accelerate the approval process. The modular production system of manufacturers reduces contamination threats while enabling better scalability which transforms product management and enables quick responses to animal disease outbreaks that spread between countries.

02

Restraint: Stringent regulatory approval pathways and complex compliance standards prolong time to market for innovative veterinary biologics

The growing attention toward animal vaccines and veterinary immunotherapies and new biologic therapeutics leads to longer development periods and more complex clinical trials which forces companies to spend their capital on regulatory affairs instead of building their product pipelines; the resulting delayed product approvals and occasional need for re submissions reduce short term revenue potential while restricting access to new veterinary biologics for livestock health and companion animal disease prevention thus creating market growth constraints and delayed adoption of advanced veterinary biologics.

03

Opportunity: Expanding Sub Saharan African smallholder livestock systems accelerating uptake of affordable diagnostic kit veterinary biologics and Intensive Southeast Asian aquaculture disease challenges boosting demand for oral immunostimulant veterinary biologics solutions

The growing smallholder poultry and goat operations across Sub Saharan Africa lack proper viral and parasitic disease diagnosis which creates opportunities for affordable veterinary biologics diagnostic kits. The global market for diagnostic kits leads all other segments because it reached USD 1.27 billion in 2024 and experts predict it will reach USD 1.71 billion by 2030 at a 5.16% annual growth rate. The most promising opportunity emerges from pen side tests which can be combined with vaccination programs and micro finance to help NGOs and cooperatives and mobile vets track herd health and execute specific immunization programs.

The increasing number of bacterial and viral outbreaks in shrimp and finfish farms throughout Vietnam and Thailand and Indonesia demonstrates the need for immunostimulant veterinary biologics which help farms decrease their antibiotic usage. The global market for immunomodulators and immunostimulants reached USD 0.51 billion in 2024 and experts predict it will expand to USD 0.73 billion by 2030 at 6.1% annual growth rate. The water stable oral and in feed biologics market for intensive tropical aquaculture will experience the most rapid growth because of collaborations between vaccine developers and feed manufacturers and major seafood exporters.

04

Challenge: High manufacturing costs and cold chain logistics constraints elevate prices and restrict veterinary biologics accessibility

The combination of advanced biologic manufacturing systems and strict quality control measures and specialized bioreactors drives up production expenses while biopharmaceutical cold chain distribution creates operational challenges and product deterioration risks that affect both new markets and remote veterinary services. The high production expenses for veterinary biologics result in premium pricing which makes conventional animal health products more attractive to cost conscious livestock producers and some wearable pet owners, thus reducing market penetration and creating significant revenue gaps between developed and developing areas.

Supply Chain Landscape

1

Veterinary Biologics R&D

Boehringer Ingelheim Animal HealthCeva Sant AnimaleElanco Animal Health
2

Antigen Production

Biognesis BagElanco Animal HealthHester Biosciences
3

Cold-Chain Distribution

Boehringer Ingelheim Animal HealthCeva Sant AnimaleElanco Animal Health
4

End Use

livestock health vaccinescompanion animal vaccinespoultry immunization
Veterinary Biologics - Supply Chain

Use Cases of Veterinary Biologics in Infectious Disease Prevention & Diagnostic Testing

Infectious Disease Prevention : The prevention of infectious diseases represents the biggest and most well established use of veterinary biologics because vaccines and immunoglobulins and antitoxins and immunomodulators and immunostimulants create lasting active or passive immunity in pets and large animal groups; Veterinary Hospitals & Clinics operate as the main distribution network for mass vaccination and booster programs which generated USD 1.60 billion in 2024 revenue and expect 6.7% annual growth until 2030. The veterinary diagnostic laboratory sector operates with USD 1.20 billion annual revenue and 4.6% annual growth rate to perform serological tests and vaccine effectiveness assessments through dedicated diagnostic tools. The veterinary biologics market demonstrates high demand because monoclonal antibodies account for 22.6% of sales and immunoglobulins & antitoxins represent 20.1% and immunomodulators & immunostimulants make up 16.4% of the market which supports livestock disease control programs that decrease death rates and boost production while reducing antibiotic usage. The segment leaders Boehringer Ingelheim Animal Health and Elanco Animal Health maintain their market dominance through their extensive prophylactic product lines and worldwide distribution capabilities. The companies Ceva Sant Animale and Biognesis Bag specialize in ruminant and poultry disease prevention programs for emerging markets while Hester Biosciences uses affordable production to increase preventive biologic availability throughout Asian markets with high growth potential. The companies work together to establish preventive animal health standards and regulatory requirements.
Veterinary Dermatology : The veterinary field of dermatology now uses monoclonal antibodies and precision immunomodulators and immunostimulants to treat allergic and atopic skin diseases through targeted biologic therapies which provide fast relief from itching and extended symptom management without causing major side effects compared to corticosteroids; these extended release injectable medications receive primary administration at Veterinary Hospitals & Clinics because clinicians select them for ongoing cases because of their reliable response patterns and simple administration schedules and better patient compliance; The market demand for monoclonal antibodies reaches 22.6% because veterinarians increasingly adopt these agents for their ability to provide long lasting itch relief and controlled symptoms with minimal side effects compared to corticosteroids; Boehringer Ingelheim Animal Health and Elanco Animal Health maintain their position as leaders in companion animal health through their dedicated research efforts and their professional education programs and lifecycle management approaches which help veterinarians adopt dermatology focused veterinary biologics; Ceva Sant Animale and Hester Biosciences support the market through their additional dermatologic solutions which veterinarians can use to enhance biologic treatment outcomes for complete skin health management.
Diagnostic Testing : The veterinary biologics market experiences rapid growth because diagnostic testing platforms now integrate these products into advanced diagnostic kits which perform fast infectious agent and immune response and oncology biomarker detection at veterinary clinics and specialized labs. The product demand share for these kits reached 40.90% in 2024 because Veterinary Diagnostic Labs and Veterinary Hospitals & Clinics adopted these platforms to support vaccination planning and treatment monitoring and herd health optimization through improved testing therapeutic feedback. The leading animal health companies Boehringer Ingelheim Animal Health and Elanco Animal Health and Ceva Sant Animale and Biognesis Bag and Hester Biosciences combine their vaccines and therapeutic biologics with diagnostic kits and surveillance systems to improve customer retention and differentiate their services while collecting better clinical data for enhanced disease management.

Recent Developments

The veterinary biologics field shows fast paced development through new recombinant vaccines and monoclonal antibodies and immunotherapeutic products which serve both companion animals and livestock. The increasing number of zoonotic diseases and antimicrobial resistant infections drives veterinarians to choose biologic products instead of conventional pharmaceuticals for their patients. The regulatory framework for biosimilars and new adjuvants continues to develop which enables quicker market entry for these products.

May 2023 : The U.S. FDA granted Zoetis approval for Librela which represents the first monoclonal antibody treatment for canine osteoarthritis pain management thus marking a significant achievement for veterinary biologics in companion animal healthcare.
January 2023 : The USDA granted Dalan Animal Health a conditional license to market the worlds initial honeybee vaccine against American foulbrood which expanded veterinary biologics beyond traditional livestock immunization to establish a premium market for pollinator health biologics.

Impact of Industry Transitions on the Veterinary Biologics Market

As a core segment of the Other Healthcare industry, the Veterinary Biologics market develops in line with broader industry shifts. Over recent years, transitions such as Shift To Precision Immunotherapies and Digitally Orchestrated Supply Chains have redefined priorities across the Other Healthcare sector, influencing how the Veterinary Biologics market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Shift To Precision Immunotherapies

The Veterinary Biologics market is undergoing a significant transition towards precision immunotherapies, driven by advanced biotechnology platforms such as recombinant vaccines and monoclonal antibodies tailored for both companion animals and livestock. This shift not only accelerates product development timelines but also enhances specificity in vaccine formulation, aligning with human biologic development practices. The integration of contract development and manufacturing organizations with animal diagnostics and genomic testing labs fosters a collaborative R&D ecosystem, facilitating technology transfer and establishing standardized quality systems. Strategically, this transition is poised to add an estimated $128 million in revenue to the Veterinary Biologics industry by 2030, underscoring its critical role in enhancing market value and operational efficiency in the U.S. and China. This industry transition is expected to add $128 million in the industry revenue between 2024 and 2030.
02

Digitally Orchestrated Supply Chains

The veterinary biologics market development has led companies to adopt digitally managed supply chains which combine cold chain logistics with serialized packaging and data based demand prediction systems. The digital transformation improves regulatory adherence and enables immediate pharmacovigilance monitoring and better management of essential livestock health products which results in lower waste and stockout occurrences in new market areas. The industry transition has led to new investments in animal health analytics and farm management platforms and IoT enabled storage solutions which transform the veterinary distribution sector and agricultural logistics and insurance underwriting and sustainability certification programs for biologics based sustainable livestock farming.

Related Reports
Loading related reports...